70Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Romania
Neuroscience Intelligence
Romania neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #36 of 50 · Data maturity A · Research score 31.1 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
16Recruiting trials
23Publications
18Institutions
Executive interpretation
Romania ranks #36 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Hoffmann-La Roche51 recruiting
Boehringer Ingelheim40 recruiting
Merck Sharp & Dohme LLC33 recruiting
Eli Lilly and Company30 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
UCB Pharma30 recruiting
Novartis20 recruiting
Celgene20 recruiting
Bristol-Myers Squibb22 recruiting
Eisai Limited20 recruiting
Disease activity
Epilepsy14trials
Parkinsons10trials
Alzheimers9trials
Multiple Sclerosis8trials
Schizophrenia5trials
Stroke4trials
Neuromuscular3trials
Neurodevelopmental Other3trials
Other Neurology3trials
Depression2trials
Research institutions
Iuliu Hațieganu University of Medicine and PharmacyOpenAlexlinked institution
National School of Public Health, Management and Professional DevelopmentOpenAlexlinked institution
Bucharest University of Economic StudiesOpenAlexlinked institution
National Institute for Laser Plasma and Radiation PhysicsOpenAlexlinked institution
Universitatea Națională de Știință și Tehnologie Politehnica BucureștiOpenAlexlinked institution
Victor Babeș University of Medicine and Pharmacy TimișoaraOpenAlexlinked institution
Romanian AcademyOpenAlexlinked institution
University of BucharestOpenAlexlinked institution
Grigore T. Popa University of Medicine and PharmacyOpenAlexlinked institution
Institute of Oncology Prof. Dr. Ion ChiricutaOpenAlexlinked institution
Clinical evidence trail
NCT07424404A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRECRUITING
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRECRUITING
NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RECRUITING
NCT06315322A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence EpilepsyACTIVE_NOT_RECRUITING
NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
Research evidence trail
PUBMEDLinking childhood adversity with borderline and depressive symptoms: the role of reward processing.2026-12-01
PUBMEDNeuroimaging anxious children and adolescents before and after cognitive behavioral therapy: a systematic review.2026-12-01
PUBMEDA ketamine/methionine exposure paradigm, alone or combined with Lactobacillus rhamnosus GG, assessing schizophrenia-relevant behavioral, oxidative stress, and molecular endpoints in adult zebrafish.2026-11-01
PUBMEDPrecision Medicine in Epilepsy: Diagnostic Yield by Next-Generation Sequencing and Genotype-Phenotype Findings in a Romanian Cohort.2026-10-06
PUBMEDPatterns of onset and progression of psychoses induced by psychoactive substance use.2026-10-01
PUBMEDMeta-Analysis: Parenting Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Compared to Healthy Controls.2026-10-01
PUBMEDClinical Outcomes and Treatment Characteristics of Seizure Threshold-Titrated Electroconvulsive Therapy in Schizophrenia: A 3.5-Year Retrospective Naturalistic Course-Level Study.2026-10-01
PUBMEDReal-World Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies in the Prevention of High-Frequency Episodic and Chronic Migraine in Romania-A Multicenter Retrospective Observational Study.2026-09-20
PUBMEDRNA-Based Therapeutics in Genetic Neurodevelopmental Disorders: Bridging Molecular Genetics and Precision Medicine.2026-08-28
PUBMEDCerebral Venous Sinus Thrombosis Revealing ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Inherited Thrombophilia and Concomitant Infection: Case Report and Narrative Review.2026-08-13
PUBMEDDynamic Tuning of MSC-Based Scaffolds for Neurological Protection After Brain or CNS Injury.2026-07-13
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.